Cipher Pharmaceuticals Inc. - Third Quarter 2026 Financial Results Call - CIPHER PHARMACEUTICALS INC

Financial Performance:

• Third quarter 2026 net revenue was $12.7 million (down 1% YoY), while year-to-date revenue was $37.3 million (down 3% YoY).
• Net income for Q3 was $10.9 million ($0.42 per diluted share), significantly increased from $5.5 million in the prior year period, driven by arbitration-related windfalls; year-to-date net income was $21.1 million ($0.81 per share).
• Adjusted EBITDA was $7.2 million for Q3 (57% margin) and $21.8 million for the nine months ended September 30, 2026 (58% margin, up from 55% prior year).
• Arbitration award recognition contributed $2.3 million in other operating income, $2.2 million in SG&A recovery, and $0.5 million in interest; $5.7 million cash received from this award in October.
• Gross margin remained robust at 82% for Q3 and 81% for year-to-date, reflecting high profitability despite lower gross profit volumes.
• SG&A expenses dropped 68% to $1.2 million in Q3 and 41% to $7.5 million year-to-date, excluding non-recurring legal costs; operational efficiencies and prior-year restructuring costs were key drivers.
• Cash position improved to $15.3 million at quarter-end, rising to approx. $20 million post-quarter following the arbitration payment; company remains debt-free with $65 million undrawn credit facility available.
• Licensing revenue surged 62% YoY to $1.2 million in Q3 and 17% to $3.5 million year-to-date, driven by Absorica and LipoFin shipments.

Guidance and Future Outlook:

• New drug submission for Netroba accepted by Health Canada; regulatory review results expected in Q1 2027 for Canadian head lice and scabies indications.
• Management expects public funding expansion for Epirus in key Canadian jurisdictions (BC, Quebec, Alberta) to drive future market share growth and addressable market expansion.
• Company remains optimistic about closing business development transactions (in-licensing, company acquisition, or out-licensing) in the short term, though specific timelines were not disclosed.
• U.S. growth strategy focuses on shifting Netroba sales from Medicaid to commercial payers, direct-to-patient, and retail channels to offset Medicaid volume declines.
• Long-term goal includes expanding Netroba and Epirus into international markets where resistance to existing treatments is high.

Business Segments and Product Lines:

• Netroba (U.S.): Q3 revenue $7.1 million (down 12% YoY) due to Medicaid coverage reductions; however, showed 14% sequential growth in Q3 versus 2% decline last year.
• Epirus (Canada): Q3 revenue $3.9 million (up 8% YoY); market share increased to 48.7% (up 1.6 points from June) driven by public drug plan listings.
• Product Portfolio: Strong performance in Puris (Epirus) and licensing partners; Netroba authorized generics saw a 12% decline.
• Strategic Partnerships: Discussions ongoing with Sun Pharmaceuticals regarding Absorica marketing extension; also evaluating proposals from other generic manufacturers.
• New Hires: Appointed Rajiv De Silva to the Board in September to leverage his 30+ years of M&A and healthcare leadership experience.

Market and Competitive Landscape:

• Netroba Market Position: Identified as a superior solution for permethrin-resistant head lice and scabies; facing resistance in Canadian markets where existing head lice treatments are less effective.
• Epirus Market Position: Market leader in Canadian isotretinoin; gaining share through public reimbursement access which was previously unavailable for significant patient populations.
• Competitive Pressure: Netroba sales impacted by reduced Medicaid covered lives; Netroba faces competition from generic options in OTC channels for head lice.
• Global Opportunity: High unmet need for effective head lice/scabies treatments globally, creating out-licensing opportunities for Netroba outside North America.
• Partnerships: Active engagement with consulting firm to bolster out-licensing efforts for Netroba and Epirus, resulting in increased global interest.

Risks and Challenges:

• Medicaid Volatility: Continued exposure to volume reductions in Medicaid covered lives impacts Netroba sales, requiring diversification into commercial channels.
• Regulatory Timelines: Future revenue from Netroba Canada depends on the speed of Health Canada approval expected in Q1 2027.
• Acquisition Uncertainty: Business development activities (M&A, in-licensing, out-licensing) involve variable time horizons with no guarantee of realization.
• Concentration: Revenue remains heavily reliant on Netroba and Epirus, though the company is debt-free and cash-rich to weather potential fluctuations.
• Legal/Arbitration: While the arbitration win provided a windfall, the $4.2M compensatory damages and 15% royalty are one-time/non-recurring items not reflective of core operations.

Management Commentary and Tone:

• Tone is confident and positive, emphasizing the company's "highly profitable" status and "debt-free" balance sheet.
• Management expressed optimism regarding the Netroba sequential turnaround and the strategic value of the arbitration award.
• CEO Craig Mull highlighted the board's strengthened M&A capability with the new director and reiterated commitment to the three-pronged growth strategy.
• CFO Ryan Mailing noted the non-recurring nature of the arbitration windfall in EBITDA calculations but celebrated the improved cash position.
• Management was cautious about providing specific timelines for M&A deals to avoid price leverage by vendors.

Analyst Questions and Answers:

• Medicaid Step-Through (Andre Uden): Confirmed ongoing pursuit of step-through processes in other states; noted decisions are clinical and state-specific with no fixed timeline.
• Walmart Pipeline Fill (Andre Uden): Declined to quantify specific units due to contract sensitivities; confirmed stocking is occurring across all U.S. Walmart stores.
• Capital Deployment (Justin Keywood): Discussed balancing share buybacks (NCIB vs. SIB) against acquisition opportunities; SIB considered more effective than restrictive NCIB.
• Acquisition Timeline (Justin Keywood): Expressed expectation to close a deal "in the short term," prioritizing U.S. infrastructure expansion and potential Canadian opportunities.
• Netroba Market Share Drivers (Doug Lowe): Confirmed ability to capture share from permethrin-resistant strains is a material driver; highlighted heavy marketing investment to educate prescribers and patients.
• Galderma Partnership (Doug Lowe): No new LIDO platform projects identified recently, but continuous communication with Galderma for future opportunities.

Other Key Points:

• The arbitration court ruled in CIFR's favor regarding clinical data ownership and remedies, affirming the $4.2M Canadian award plus a 15% royalty on Zorica LD (Absorica LD equivalent) sales in Canada through 2040.
• Total operating expenses (excluding arbitration items) dropped 32% year-to-date due to operational efficiencies and reduced non-recurring legal costs.
• The company has engaged a consulting firm to assist with out-licensing Netroba and Epirus globally, as well as identifying in-licensing targets.
• Netroba sales in the U.S. are seeing a sequential improvement despite the 12% YoY decline, attributed to marketing efforts and expanded commercial payer initiatives.